The Food and Drug Administration advisory panel was about as good as InterMune
The advisory panel voted 9-3 that the drug should be approved. Not a bad showing, but as I mentioned earlier this week, other drugmakers, including Dendreon
It should also be noted that the committee voted 7-5 that "pirfenidone provides a clinically meaningful beneficial effect in the treatment of patients with IPF to reduce decline in lung function." I'm not exactly sure why two committee members voted that there isn't evidence that pirfenidone works, but still voted for approval of the drug. Given the circumstances of the mixed clinical trial results, the FDA may be more interested in the closer vote about whether the drug worked.
We should know by May 4 whether the drug wins approval. That's assuming no more snowstorms hit Washington, which pushed back the PDUFA date for once-weekly Byetta from Amylin Pharmaceuticals
Given the high uncertainty about weather (sorry) an approval would come, InterMune has conserved its cash, and it hasn't built out a sales force or commercial supply of the drug. If there is an approval on May 4, don't expect pirfenidone, which would then be called Esbriet, to launch on May 5.
Is InterMune a buy here? Obviously, that depends on what the FDA does -- which still isn't clear in my opinion. There's still plenty of room to run from its current $1.8 billion market cap if -- and that's a big if -- the FDA does approve the drug.
There are roughly 200,000 patients with idiopathic pulmonary fibrosis (IPF) in Europe and the U.S. If half take the drug at a price of about $10,000 to $15,000 per year, that gives annual revenue on the order of $1 billion to $1.5 billion. At a sales multiple of about three to five -- similar to where other biotechs with a drug on the market have traded -- that gives a market cap of about $3 billion to $7.5 billion. Yeah, I'd call that a significant upside potential.
There are a lot of assumptions there about how patients, InterMune, and investors will react after an approval, assuming it comes. I tried to stay fairly conservative, especially on the patient uptake and price (that's near the lower end of where Actimmune has sold, including its off-label use to treat IPF, according to InterMune management), as well as the sales multiple. Also keep in mind that this includes InterMune's marketing the drug in the EU, where it's under review.
Another double or more from here is certainly possible. Just realize that InterMune could easily go back to where it started if, a few short weeks from now, the FDA sends the company back to the drawing board.
If you'd like further analysis on InterMune, grab a free trial of Motley Fool Rule Breakers, where InterMune has been a pick since 2006.
More from The Motley Fool
InterMune Inc. Shareholders Can Now Breathe Easier Thanks to Roche
Roche stuns Wall Street and investors by snatching up InterMune and its first-in-class lung disease drug. But, does this deal make sense?
3 Stocks to Get on Your Watchlist
A biotech with a newly approved drug, a potentially cheap banking giant, and a possibly overvalued clinical-stage biotech with a promising rare-disease drug are this week's must-watch stocks.
The 3 Biggest Biotech Wins of the Week
See who released the best clinical results during the week ending May 25.